Purpose: To report the findings of the clinical and molecular evaluation in a Greek family with fleck corneal dystrophy (CFD). Methods: A 58-year-old woman was seen on routine ophthalmic examination and diagnosed as having CFD. All available family members were examined to evaluate the clinical findings and inheritance of the disease. Twenty members of the family in five generations underwent slit-lamp examination. Eleven were females and nine males, aged from two years to 85 years old. Blood samples were available from four patients with CFD and seven unaffected relatives, and the DNAs were subjected to molecular screening of the phosphoinositide kinase, five finger-containing (PIKFYVE) gene by direct sequencing or denaturing high performance liquid chromatography (DHPLC).
Fleck corneal dystrophy (CFD, OMIM 121850) is a rare autosomal dominant stromal dystrophy beginning early in life and is characterized by flat, gray-white, tiny flecks scattered throughout the stroma. The flecks have comma, oval, circular or stellate shapes. Histologically only abnormal keratocytes are involved, which contain excess glycosaminoglycan and complex lipids. Typically, the stroma in between the flecks is clear, and the endothelium, epithelium, Bowman layer, and Descemet membrane are normal. The flecks in CFD may appear as early as at two years of age or even at birth, and generally they are reported not to progress significantly throughout life. Although CFD is thought to be rare, specific incidence figures are difficult to obtain. François and Neetens described the condition for the first time in 1957 [1] . Several reports have proven the autosomal dominant pattern of inheritance of this corneal dystrophy [2] [3] [4] . CFD has been linked to chromosome 2q35 [5] due to mutations in the phosphoinositide kinase, five finger-containing (PIKFYVE) gene, also known as PIP5K3 (phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase type III) [4] . PIKFYVE belongs to a large family of lipid kinases that alter the phosphorylation status of intracellular phosphatidylinositol [6] . The content of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) in endosomal membranes changes dynamically with fission and fusion events that generate or absorb intracellular transport vesicles. PIKFYVE is the PtdIns(3,5)P2-producing component of a trimolecular complex that tightly regulates the level of PtdIns(3,5)P2. Other components of this complex are the PIKFYVE activator VAC14 and the PtdIns(3,5)P2 phosphatase FIG4 [7] . In addition to its phosphoinositide 5-kinase activity, PIKFYVE also has protein kinase activity [8] . PIKFYVE contains 41 coding exons spanning more than 89 kb, and encodes a 2,089-amino acid protein [4] .
In this study we present on the clinical and molecular genetic examinations performed on CFD patients and unaffected relatives in a five generation family of Greek origin. salting out procedure [9] . Coding exons and adjacent intronic sequences of PIKFYVE were amplified from genomic DNA of the proband ( 10 μl. Products of the sequencing reactions were purified using the Performa DTR gel-filtration system (Edge BioSystems, Gaithersburg, MD) and were run on a 3100 ABI genetic analyzer (Applied Biosystems). Sequences were aligned with the reference genomic sequence (GenBank NM_015040) using the Seqman program of the DNASTAR package (DNASTAR, Inc., Madison, WI) or Chromas, version 2.23 (Technelysium Pty Ltd, Brisbane, Australia). The primer sets and annealing temperatures used are shown in Appendix 1. Denaturing high performance liquid chromatography (DHPLC) was used to test co-segregation by verifying the results of direct sequencing of the proband to the other affected patients (Figure 1 , II:2, III:11, and III:13). PCR products were screened on a WAVE system (Transgenomics, UK) at a temperature of 60.1 °C and starting at 58.5% B buffer. Written informed consent was obtained from all participants. The clinical and molecular examinations were in accordance with the Helsinki Declaration. mutation was not observed in 96 control individuals or in more than 25 patients with CFD previously analyzed in our laboratory.
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Mutations in PIKFYVE have been implicated as the major cause of CFD, an autosomal dominant human disease characterized by the presence of numerous white flecks scattered in all layers of the stroma [4] . PIKFYVE is a protein important for post-Golgi vesicle processing. Mammalian PIKFYVE is a member of an evolutionarily ancient gene family of PtdIns(3,5)P2-synthesizing enzymes that are large proteins, represented by a single-copy gene in most, if not all, species with sequenced genomes, including the zebrafish [10, 11] . Most of the reported mutations are of nonsense and frameshift type and occur in and around the Cpn60_TCP1 domain, predicting termination of the peptide before the catalytic domain. Although the activity of the PIKFYVE protein or the PtdIns(3,5P)2 levels have not been determined under these conditions, it is expected that the mutations will result in a loss of PIKFYVE function. Given the lethality of the PIKfyve null mutations in model organisms [10] , the asymptomatic condition of the CFD patients is quite surprising but could be attributed to the presence of one normal allele. Histological findings in CFD indicating that the corneal flecks are swollen keratocytes containing membranelimited empty vacuoles [12] , are consistent with the phenotypic changes seen under perturbed PIKfyve functionality [10] .
In this study we reported our findings on the clinical evaluation and the molecular genetic examination of a family presenting CFD. To our knowledge, this is the first reported family of Greek origin. The pedigree (Figure 1 ) consisted of a total of 40 individuals in five generations, among which 20 were subjected to clinical evaluation, whereas 20 were not. Among the 20 examined, six were found to be affected by CFD (Figure 1 Figure 6 ). This 4-bp deletion was further found to be the cause of a frameshift leading to the p.P968Vfs23 alteration on the protein level. The mutation was confirmed in all affected patients from which bloods were drawn ( Figure 1 , II:2, III:11, III:13) by DHPLC analysis using the WAVE technology. We conclude that the novel c.3060-3063delCCTT (p.P968Vfs23) mutation in PIKFYVE, which segregated with the disease, was the causative mutation in this family.
